GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » NKY Medical Holdings Ltd (SZSE:300109) » Definitions » EBIT

NKY Medical Holdings (SZSE:300109) EBIT : ¥575 Mil (TTM As of Mar. 2024)


View and export this data going back to 2010. Start your Free Trial

What is NKY Medical Holdings EBIT?

NKY Medical Holdings's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was ¥144 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was ¥575 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. NKY Medical Holdings's annualized ROC % for the quarter that ended in Mar. 2024 was 14.90%. NKY Medical Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 32.98%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. NKY Medical Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 8.82%.


NKY Medical Holdings EBIT Historical Data

The historical data trend for NKY Medical Holdings's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NKY Medical Holdings EBIT Chart

NKY Medical Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 207.71 118.59 325.83 391.09 587.43

NKY Medical Holdings Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 156.32 178.66 186.96 65.49 144.02

Competitive Comparison of NKY Medical Holdings's EBIT

For the Drug Manufacturers - General subindustry, NKY Medical Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NKY Medical Holdings's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, NKY Medical Holdings's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where NKY Medical Holdings's EV-to-EBIT falls into.



NKY Medical Holdings EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥575 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NKY Medical Holdings  (SZSE:300109) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

NKY Medical Holdings's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

ROC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=600.172 * ( 1 - 15.38% )/( (3321.165 + 3495.161)/ 2 )
=507.8655464/3408.163
=14.90 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=4019.691 - 373.554 - ( 324.972 - max(0, 426.948 - 1187.002+324.972))
=3321.165

Invested Capital(Q: Mar. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=4109.82 - 331.724 - ( 282.935 - max(0, 395.55 - 1164.363+282.935))
=3495.161

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

NKY Medical Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=576.096/( ( (1316.791 + max(377.177, 0)) + (1387.804 + max(411.406, 0)) )/ 2 )
=576.096/( ( 1693.968 + 1799.21 )/ 2 )
=576.096/1746.589
=32.98 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(344.13 + 309.802 + 122.399) - (373.554 + 0 + 25.6)
=377.177

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(371.638 + 281.905 + 120.975) - (331.724 + 0 + 31.388)
=411.406

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

NKY Medical Holdings's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2024 )
=575.133/6521.630
=8.82 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NKY Medical Holdings EBIT Related Terms

Thank you for viewing the detailed overview of NKY Medical Holdings's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


NKY Medical Holdings (SZSE:300109) Business Description

Traded in Other Exchanges
N/A
Address
No.9 Zhongshan Road, Boai county, Jiaozuo, Henan, CHN, 454450
NKY Medical Holdings Ltd develops and manufactures polyvinylpyrrolidone (PVP) series products in China. Its products can be used in Pharmaceutical accessories, hair gel, wine products stabilizer, water treatment, glue stick, and oral care products.
Executives
Zhang Jun Zheng Directors, executives
Yang Hong Bo Director
Wang Dong Hu Director
Ren Da Long Director
Xing Xiao Liang Directors, executives
Zou Xiao Wen Executives
Wang Shi Gang Executives
Wang Xin Meng Executives
Qu Yun Xia Supervisors
Wang Jian Qiang Director
Yang Hai Jiang Director
Yan Zhong Chao Supervisors
Liu Ai Min Executives
Wu Cong Zhou Executives
Wu Wen Bin Director

NKY Medical Holdings (SZSE:300109) Headlines

No Headlines